142 related articles for article (PubMed ID: 34560229)
1. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
[TBL] [Abstract][Full Text] [Related]
2. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
3. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
Li S; Sheng J; Liu Z; Fan Y; Zhang C; Lv T; Hu S; Jin J; Yu W; Song Y
J Cell Mol Med; 2021 Mar; 25(5):2436-2449. PubMed ID: 33507584
[TBL] [Abstract][Full Text] [Related]
5. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
6. The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory.
MacCallum PE; Blundell J
Psychopharmacology (Berl); 2020 Sep; 237(9):2795-2808. PubMed ID: 32601986
[TBL] [Abstract][Full Text] [Related]
7. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
[TBL] [Abstract][Full Text] [Related]
8. An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
Mizutani Y; Inase A; Maimaitili Y; Miyata Y; Kitao A; Matsumoto H; Kawaguchi K; Higashime A; Goto H; Kurata K; Yakushijin K; Minami H; Matsuoka H
Int J Hematol; 2019 Oct; 110(4):490-499. PubMed ID: 31286402
[TBL] [Abstract][Full Text] [Related]
9. Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.
Fantus D; Dai H; Ono Y; Watson A; Yokota S; Mohib K; Yoshida O; Ross MA; Watkins SC; Ramaswami B; Valusjkikh A; Rothstein DM; Thomson AW
Transplantation; 2017 Dec; 101(12):2830-2840. PubMed ID: 28885497
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice].
Liao H; Wang Y; Xu X; Zhou C; Zhang J; Zhong K; Yang D
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jul; 41(7):1056-1061. PubMed ID: 34308856
[TBL] [Abstract][Full Text] [Related]
11. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL
Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163
[TBL] [Abstract][Full Text] [Related]
12. AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest.
Yu CC; Huang HB; Hung SK; Liao HF; Lee CC; Lin HY; Li SC; Ho HC; Hung CL; Su YC
PLoS One; 2016; 11(3):e0151942. PubMed ID: 27031247
[TBL] [Abstract][Full Text] [Related]
13. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
14. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
15. mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both
Liao HF; Lin YZ; Yu CC; Tai TS; Hung SK; Yang CC; Su YC
Anticancer Res; 2019 Sep; 39(9):4829-4835. PubMed ID: 31519585
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
17. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia.
Hadley G; Beard DJ; Alexopoulou Z; Sutherland BA; Buchan AM
Neurosci Lett; 2019 Jul; 706():223-230. PubMed ID: 31100427
[TBL] [Abstract][Full Text] [Related]
20. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Komura N; Mabuchi S; Shimura K; Yokoi E; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Cancer Immunol Immunother; 2020 Dec; 69(12):2477-2499. PubMed ID: 32561967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
